Trifluoromethanesulfonic Acid

Trifluoromethanesulfonic Acid

SCHEMBL78630

O=S(=O)([O-])C(F)(F)F.O=S(=O)([O-])C(F)(F)F.O=S(=O)([O-])C(F)(F)F.[Y+3]

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.44
CA2 P00918 2/20 0.44
CA7 P43166 1/20 0.44
CA13 Q8N1Q1 1/20 0.44
GPR3 P46089 2/20 0.42
ACHE P22303 2/20 0.33
KCNH2 Q12809 6/20 0.31
MEN1 O00255 1/20 0.31
ALDH1A1 P00352 1/20 0.31
TSHR P16473 1/20 0.31
KMT2A Q03164 1/20 0.31
F2 P00734 1/20 0.30
PRSS1 P07477 1/20 0.30
PRSS2 P07478 1/20 0.30
PRSS3 P35030 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoromethanesulfonic Acid SCHEMBL6686915 1.00 CA1 (0.44) CA1CA2CA7CA13GPR3
Trifluoromethanesulfonic Acid SCHEMBL20678154 0.96 CA1 (0.41) CA1CA2CA7CA13GPR3
Trifluoromethanesulfonic Acid SCHEMBL5590788 0.96 CA1 (0.41) CA1CA2CA7CA13GPR3
Trifluoromethanesulfonic Acid SCHEMBL25285896 0.92 CA1 (0.44) CA1CA2CA7CA13GPR3
Trifluoromethanesulfonic Acid SCHEMBL25301943 0.92 CA1 (0.44) CA1CA2CA7CA13GPR3
Trifluoromethanesulfonic Acid SCHEMBL25292546 0.92 GPR3 (0.48) CA1CA2CA7CA13GPR3
Trifluoromethanesulfonic Acid SCHEMBL25292878 0.92 CA1 (0.44) CA1CA2CA7CA13GPR3
Trifluoromethanesulfonic Acid SCHEMBL20570425 0.92
Trifluoromethanesulfonic Acid SCHEMBL117665 0.92 CA1 (0.44) CA1CA2CA7CA13GPR3
Trifluoromethanesulfonic Acid SCHEMBL23430060 0.92 CA1 (0.44) CA1CA2CA7CA13GPR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1673 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122079748-A Guaazulene triarylmethane, synthesis method and application thereof in preparation of antibacterial products 2026-05-26 CN claimed
CN-122010956-A Chiral 1, 4-diazabicyclo [3.1.1] heptane derivatives, synthesis and application thereof 浙江师范大学 2026-05-12 CN claimed
CN-122010969-A Aminated 20 (S) -10, 11-difluoro methylenedioxy camptothecin derivative, and preparation method and application thereof 浙江工业大学 2026-05-12 CN claimed
CN-121574135-A Method for synthesizing 7-oxa-2-azabicyclo [3.3.1] non-3-alkene-1-alcohol by rare earth catalysis 北京化工大学 2026-02-27 CN claimed
US-20250368599-A1 PROCESS FOR THE PREPARATION OF CYCLOHOMOGERANATES BASF SE (DE) 2025-12-04 US claimed
EP-4626954-A2 RING OPENING POLYMERIZATION OF CYCLIC SILOXANES CHT USA INC. (US) 2025-10-08 EP claimed
CN-120199887-A Covalent organic framework composite polymer electrolyte and preparation method and application thereof 华中科技大学 2025-06-24 CN claimed
CN-120058733-A Organic conjugated small molecule and preparation method thereof 电子科技大学 2025-05-30 CN claimed
WO-2025102108-A1 CATALYTIC DEGRADATION OF PEROXIDE-BASED EXPLOSIVES NEWSOUTH INNOVATIONS PTY LIMITED (AU) 2025-05-22 WO claimed
CN-120004790-A Synthesis method of spiro oxindole, ke Nayin and yohimbine alkaloid and derivatives thereof 中国科学院昆明植物研究所 2025-05-16 CN claimed
US-20030233011-A1 Preparation of levulinic acid esters and formic acid esters from biomass and olefins; compositons prepared thereby; and uses of the compositions as fuel additives E.I. DU PONT DE NEMOURS AND COMPANY 2003-12-18 US claimed
US-6664402-B2 Continuous hydrogenation process E. I. DU PONT DE NEMOURS AND COMPANY 2003-12-16 US claimed
WO-2003085071-A1 PREPARATION OF LEVULINIC ACID ESTERS AND FORMIC ACID ESTERS FROM BIOMASS AND OLEFINS E.I. DU PONT DE NEMOURS AND COMPANY (US) 2003-10-16 WO claimed
US-20030109724-A1 Manufacture of 3-methyl-tetrahydrofuran from alpha-methylene-gamma-butyrolactone in a two step process INVISTA NORTH AMERICA S.A.R.L. 2003-06-12 US claimed
US-20030065198-A1 By hydrogenation INVISTA NORTH AMERICA S.A.R.L. 2003-04-03 US claimed
US-6383682-B1 ACTIVE MATERIAL CAPABLE OF REVERSIBLE ACCEPTING AND YIELDING YTTRIUM IONS TELCORDIA TECHNOLOGIES, INC. 2002-05-07 US claimed
US-20020010374-A1 Continuous process for the preparation of polytrimethylene ether glycol DUPONT INDUSTRIAL BIOSCIENCES USA, LLC 2002-01-24 US claimed
EP-0658552-B1 Process for the preparation of alpha-tocopherol derivatives EISAI CO LTD (JP) 1999-03-31 EP claimed
US-5532387-A CYCLIZATION OF TRIMETHYLHYDROQUINONE AND AN ALKENYL ALCOHOL, REUSABLE CATALYST, IIIB FLUOROSULFONATE, NITRATE, SULFATE, OR FLUOROALKYLSULFONATE EISAI CO., LTD. (JP) 1996-07-02 US claimed
EP-0658552-A1 Process for the preparation of alpha-tocopherol derivatives Eisai Co., Ltd. (JP) 1995-06-21 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030233011-A1 Preparation of levulinic acid esters and formic acid esters from biomass and olefins; compositons prepared thereby; and uses of the compositions as fuel additives CS, FASN, CYP4F12 CA1 328/4885CA2 719/4885CA7 231/4885
US-20250368599-A1 PROCESS FOR THE PREPARATION OF CYCLOHOMOGERANATES GGPS1, FDPS, DHPS CA1 2834/4885CA2 3518/4885CA7 3303/4885
US-20030109724-A1 Manufacture of 3-methyl-tetrahydrofuran from alpha-methylene-gamma-butyrolactone in a two step process DHPS, ADH1C, ADH1A CA1 4093/4885CA2 4758/4885CA7 4393/4885
US-20030065198-A1 By hydrogenation ADH5, ADH1C, ADH1A CA1 3170/4885CA2 4366/4885CA7 3541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.